𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia

✍ Scribed by Ofer Shpilberg; Nuhad Haddad; Orit Sofer; Pia Raanani; Miriam Berkowicz; Angela Chetrit; Anna Carter; Bracha Ramot; Ilana Tatarski; Isaac Ben-Bassat

Book ID
113240121
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
459 KB
Volume
19
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Low dose interleukin-2 following intensi
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission
✍ Richard M. Stone; Daniel J. DeAngelo; Anna Janosova; Ilene Galinsky; Christine C πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 343 KB πŸ‘ 2 views

## Abstract The most important problem in the therapy of patients with acute myeloid leukemia (AML) is relapse after intensive therapy. We sought to determine if interleukin‐2 (low‐dose with intermittent boluses) administration could be feasibly administered after standard therapy to potentiate ant

Treatment of patients with recurrent and
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine : A pharmacologically based regimen
✍ David W. Sternberg; William Aird; Donna Neuberg; Lynn Thompson; Kimberly MacNeil πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 2 views

## BACKGROUND. Although chemotherapy can achieve a high rate of disease remission induction in patients with newly diagnosed acute myelogenous leukemia (AML), patients with recurrent or refractory AML generally have a poorer rate of response. This study assessed the utility of mitoxantrone and inte

Comparison of allogeneic stem cell trans
Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia
✍ Apostolia-Maria Tsimberidou; Niki Stavroyianni; Nora Viniou; Maria Papaioannou; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 148 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Postremission therapy is critical in maintaining complete remission (CR) in patients with de novo acute myelogenous leukemia (AML). The aim of this trial was to compare allogeneic stem cell transplantation (SCT), high‐dose cytarabine (ara‐C; HiDAC), and autologous SCT as